📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-15 12:25
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
14 announcements match the current filters (relevance ≥ 5).
Vivimed Labs Reports FY26 Loss of ₹1,764.73M; CIRP Initiated Under IBC
Vivimed Labs announced audited financial results for the year ended March 31, 2026, reporting a consolidated net loss of ₹1,764.73 million compared to a loss of ₹319.61 million in FY2025. Consolidated revenue from operations fell sharply to ₹695.61 million from ₹1,162.69 million in the prior year. Additionally, the company is under Corporate Insolvency Resolution Process (CIRP) admitted by the NCLT on April 15, 2026, leading to the suspension of the Board's powers and management handover to an Interim Resolution Professional (IRP). Operations were severely affected by liquidity distress, including an inventory write-down of ₹233.08 million due to unutilized working capital.
Confidence: HIGH
What changedAdmission into Corporate Insolvency Resolution Process (CIRP) as of April 15, 2026, with the Board suspended and IRP taking control, alongside severe widening of annual financial losses.
Why it mattersThe company faces extreme solvency and going-concern challenges, with working capital dried up, total net worth eroded, and operations under insolvency resolution.
FY26 Consolidated Revenue: ₹695.61 millionFY26 Consolidated Net Loss: ₹1,764.73 millionInventory Write-down: ₹233.08 millionCIRP Commencement Date: April 15, 2026
📅 Short termTrading sentiment is likely to remain severely constrained due to heavy losses and management control shifting to the insolvency resolution professional.
📈 Long termThe company's survival and continuity depend entirely on whether a viable resolution plan emerges from the CIRP process under the IBC.
⚠ Risk flags
- Insolvency proceedings (CIRP) initiated by NCLT
- Severe erosion of net worth and going-concern risk
- Active CBI investigation regarding past banking facilities
- Lack of working capital disrupting operations and inventory usability
Key Highlights
Consolidated revenue from operations dropped to ₹695.61 million in FY26 from ₹1,162.69 million in FY25
Consolidated net loss widened significantly to ₹1,764.73 million for FY26 compared to ₹319.61 million in FY25
Company admitted to CIRP by NCLT on April 15, 2026, suspending board powers under an IRP
Inventory write-down of ₹233.08 million recognized due to working capital constraints causing batch rejections and expiry
Facing CBI investigation initiated by lender SBI (currently stayed by Telangana High Court)
👀 What to Watch
Track the updates on the Corporate Insolvency Resolution Process (CIRP) and outcomes of the Committee of Creditors (CoC) meetings. Also monitor ongoing debt assignments and CBI legal proceedings.
Vivimed Labs Clarifies FY25 Financial Filing Delays and Audit Qualification Discrepancies
Vivimed Labs has responded to NSE's clarification request regarding procedural lapses in its FY25 financial result filings. The company admitted to a filing delay, submitting results on May 31, 2025, at 12:13 PM despite the board meeting concluding at 22:10 PM the previous night, citing technical scanner issues. Furthermore, the company addressed a missing MD signature on the Statement on Impact of audit qualifications and reported ongoing errors in submitting revised XBRL data. These administrative and compliance hurdles, combined with the mention of audit qualifications, signal potential internal control weaknesses.
Key Highlights
Filing delay occurred for FY25 results, with submission happening over 14 hours after the board meeting concluded on May 30, 2025.
The Statement on Impact of audit qualifications was signed by a Whole Time Director instead of the MD, who was absent from the meeting.
Discrepancies were identified in XBRL filings, and the company is currently facing technical errors while attempting to upload revised data.
The company cited 'scanner problems' and 'technical issues' as the primary reasons for the regulatory non-compliance regarding filing timelines.
👀 What to Watch
Investors should remain cautious as filing delays and audit qualifications are often indicators of poor corporate governance or internal financial controls. Monitor the company's ability to resolve XBRL discrepancies and review the specific nature of the audit qualifications once fully disclosed.
Vivimed Labs Issues Form G for Insolvency Resolution; Final Plan Deadline August 28, 2026
Vivimed Labs Limited is currently undergoing the Corporate Insolvency Resolution Process (CIRP) and has officially invited Expressions of Interest (EOI) from potential bidders. The company's financial health has deteriorated, with revenue falling from ₹136.80 Cr in FY24 to ₹103.60 Cr in FY25, and further down to ₹48.23 Cr for the first nine months of the current fiscal year. The resolution process aims to find a buyer or investor, with the final submission of resolution plans scheduled for August 28, 2026.
Key Highlights
Form G published inviting Expressions of Interest (EOI) with a submission deadline of June 29, 2026.
Revenue from operations declined to ₹48.23 Cr for the nine-month period ended December 31, 2025.
The company operates five manufacturing units, though the Bidar, Karnataka facility is currently non-operational.
Total employee and workmen count stands at 352 as per the suspended board of directors.
Final resolution plans from prospective applicants are expected to be submitted by August 28, 2026.
👀 What to Watch
Investors should exercise extreme caution as equity shareholders typically face significant dilution or total loss of value during insolvency proceedings. Monitor the list of prospective resolution applicants due on July 24, 2026, to gauge market interest in the company's assets.
Vivimed Labs Postpones Board Meeting for FY 2025-26 Financial Results
Vivimed Labs Limited has officially postponed its Board Meeting that was originally scheduled for May 30, 2026. The meeting was intended to approve the audited financial results for the quarter and full year ended March 31, 2026. The company has not yet provided a revised date, stating it will be intimated in due course. As a result, the trading window for designated persons will remain closed until 48 hours after the results are eventually declared.
Key Highlights
Board Meeting scheduled for May 30, 2026, for FY 2025-26 results approval is postponed.
The postponement affects the reporting of both the final quarter and the full financial year results.
A revised date for the meeting has not been determined yet.
Trading window for company securities remains closed for designated persons until 48 hours post-declaration.
👀 What to Watch
Investors should exercise caution and monitor for the new meeting date, as delays in reporting annual financial results can sometimes signal underlying administrative or audit-related issues.
Vivimed Labs Enters Corporate Insolvency Resolution Process (CIRP) by NCLT Order
The National Company Law Tribunal (NCLT), Bengaluru Bench, has initiated the Corporate Insolvency Resolution Process (CIRP) for Vivimed Labs Limited effective April 15, 2026. T Narayana Swamy has been appointed as the Interim Resolution Professional (IRP) to manage the company's affairs and oversee the debt resolution. Creditors are required to submit their claims by May 1, 2026, with the entire resolution process estimated to conclude by October 11, 2026. This development signals severe financial distress and poses a high risk of equity dilution or total loss for shareholders.
Key Highlights
NCLT Bengaluru Bench ordered the commencement of CIRP on April 15, 2026.
T Narayana Swamy appointed as Interim Resolution Professional (IRP) with registration number IBBI/IPA-002/IP-N01078/2020-2021/13427.
Last date for creditors to submit claims with proof is May 1, 2026.
Estimated date of closure for the insolvency resolution process is October 11, 2026.
The company's management is now vested with the IRP under the provisions of the Insolvency and Bankruptcy Code (IBC).
👀 What to Watch
Investors should exercise extreme caution as equity shareholders typically face significant value erosion or delisting during the IBC process. It is advisable to avoid new investments in the stock until the resolution plan is finalized and approved.
Vivimed Labs Admitted to Insolvency (CIRP) by NCLT Bengaluru Over ₹2.78 Crore Default
The National Company Law Tribunal (NCLT) Bengaluru Bench has admitted Vivimed Labs Limited into the Corporate Insolvency Resolution Process (CIRP) on April 15, 2026. The petition was filed by operational creditor Blue Cube Germany Assets GmbH & Co. KG for a default amounting to approximately ₹2.78 crore, including interest. Despite a 2019 civil court decree and subsequent payment undertakings in 2021, the company failed to discharge its liabilities. An Interim Resolution Professional (IRP) has been appointed to manage the company's operations and seek a resolution plan.
Key Highlights
NCLT Bengaluru admitted the company to CIRP under Section 9 of the IBC following a default on operational debt.
The default stems from a 2012 supply agreement with a total claim of ₹2.78 crore as per the demand notice.
The company failed to honor a 2019 court decree and subsequent payment memos filed in 2021.
The tribunal noted multiple other insolvency petitions are pending against the company, indicating widespread financial stress.
An Interim Resolution Professional (IRP) has been appointed, and the next hearing is scheduled for June 24, 2026.
👀 What to Watch
Investors should be extremely cautious as the initiation of CIRP typically leads to a suspension of trading and significant risk of equity wipe-out. Existing shareholders should monitor IRP reports and the resolution process closely, though recovery for equity holders is usually minimal.
Vivimed Labs Q3 FY26 Net Loss Widens to ₹165.5M; Auditors Flag ₹472M Unprovided Interest
Vivimed Labs reported a sharp decline in consolidated revenue to ₹159.89 million for Q3 FY26, down from ₹365.10 million in the previous quarter. The consolidated net loss widened to ₹165.54 million, reflecting severe operational and financial stress. Statutory auditors have issued a qualified conclusion, highlighting that the company failed to account for ₹472.37 million in interest and penal charges on loans for the nine-month period ending December 2025. Furthermore, the company is evaluating a forensic audit report from FY 2022-23, adding to the uncertainty surrounding its financial health.
Key Highlights
Consolidated revenue fell by over 50% QoQ to ₹159.89 million from ₹365.10 million.
Net loss for the quarter stood at ₹165.54 million, significantly higher than the previous quarter's ₹73.01 million loss.
Auditors flagged an understatement of liabilities as ₹472.37 million in interest and penal charges were not provided for 9M FY26.
Forensic audit report for FY 2022-23 is currently under evaluation for potential financial impact.
Standalone total expenses of ₹281.97 million significantly exceeded total revenue of ₹116.31 million.
👀 What to Watch
Investors should exercise extreme caution or consider exiting positions due to severe auditor qualifications, forensic audit concerns, and the company's inability to service debt interest. The financial transparency and operational viability of the firm are currently under significant risk.
Vivimed Labs Files for Pre-pack Insolvency (PPIRP) Over ₹512.53 Crore Default
Vivimed Labs Limited has formally filed an application for the initiation of a Pre-packaged Insolvency Resolution Process (PPIRP) under Section 54A of the IBC Act. The application was submitted to the NCLT Bengaluru Bench on February 12, 2026, following a massive debt default. As of January 31, 2026, the company reported a total default amount of ₹512.53 crores. This legal step indicates severe financial distress and a formal attempt to restructure its liabilities through the insolvency framework.
Key Highlights
Filed for Pre-pack Insolvency Resolution Process (PPIRP) with NCLT Bengaluru on February 12, 2026.
Total default amount stands at ₹512,53,06,756 (approximately ₹512.53 crores) as of January 31, 2026.
The application was filed under Section 54A of the Insolvency and Bankruptcy Code (IBC) Act.
This follows previous financial distress intimations dated November 13, 2025, and January 10, 2025.
👀 What to Watch
Investors should exercise extreme caution as insolvency proceedings typically result in significant equity dilution or total loss for shareholders. It is advisable to monitor NCLT's admission of the case and any subsequent resolution plans that may impact the company's listing status.
Vivimed Labs Secures High Court Stay on CBI Proceedings and SBI 'Fraud' Classification
Vivimed Labs has obtained an interim stay from the Telangana High Court against all further proceedings following a CBI search and seizure conducted on January 20, 2026. The legal action was triggered by State Bank of India (SBI) classifying the company's account as 'fraud', a move the court noted was already suspended in a previous writ petition. The court has restrained the CBI from taking any coercive steps against the company or its directors until further orders. While the stay provides temporary relief, the underlying fraud allegations by a major lender remain a significant risk factor.
Key Highlights
Telangana High Court granted interim stay on February 6, 2026, against CBI search and seizure actions.
The CBI raid on January 20, 2026, was based on a complaint by State Bank of India (SBI) regarding 'fraud' classification.
Court noted that the 'fraud' classification was already suspended in a prior legal proceeding (W.P.No.24697 of 2025).
The High Court has scheduled the next hearing for the matter on March 6, 2026.
👀 What to Watch
Investors should exercise extreme caution as the company faces serious fraud allegations from lenders despite the current legal stay. Closely monitor the next court hearing on March 6, 2026, for updates on the investigation's status.
Vivimed Labs CFO Phaninder Nath P S Resigns Effective February 6, 2026
Vivimed Labs Limited has announced the resignation of its Chief Financial Officer, Mr. Phaninder Nath P S, effective from the close of business hours on February 6, 2026. The resignation is attributed to personal health issues that have reportedly aggravated over the last few weeks. Consequently, he will also cease to be a Key Managerial Personnel (KMP) and Senior Management Personnel (SMP) of the company. The company will now need to initiate the process of appointing a successor to maintain financial leadership and oversight.
Key Highlights
CFO Phaninder Nath P S resigned effective February 6, 2026
Resignation is due to personal health issues aggravating over recent weeks
Cessation of role as Key Managerial Personnel (KMP) and Senior Management Personnel (SMP)
The company must now identify and appoint a new CFO to ensure financial continuity
👀 What to Watch
Investors should monitor the company's subsequent announcements regarding the appointment of a new CFO to ensure a smooth transition. While the resignation is for personal reasons, any delay in finding a qualified replacement could impact financial reporting timelines.
CBI Issues Notice to Vivimed Labs CFO and CS Over SBI Financial Irregularities Complaint
Vivimed Labs' Chief Financial Officer and Company Secretary have received a formal notice from the CBI's Banking Securities Fraud Branch following a complaint by State Bank of India (SBI). The investigation pertains to alleged financial irregularities within the company. This follows a prior development where Rare Asset Reconstruction Ltd (Rare ARC) acquired the company's financial assets and debt from SBI in October 2025. The company remains liable to Rare ARC for all outstanding dues, interest, and contractual charges.
Key Highlights
CBI Banking Securities Fraud Branch issued notice to CFO and CS on January 27, 2026.
Investigation initiated based on a complaint by State Bank of India regarding financial irregularities.
Rare Asset Reconstruction Ltd acquired SBI's financial assets in the company as of October 25, 2025.
Rare ARC is now the primary entity entitled to recover total dues and interest from Vivimed Labs.
The notice was officially communicated to the company via email on January 29, 2026.
👀 What to Watch
Investors should exercise extreme caution as a CBI investigation into financial fraud is a high-risk event that often leads to severe reputational and operational damage. The transfer of debt to an Asset Reconstruction Company further highlights the company's distressed financial position.
Vivimed Labs Trading to Resume on December 18, 2025, After Suspension Revocation
BSE and NSE have officially revoked the suspension of trading in Vivimed Labs Limited's equity shares, with trading set to resume on December 18, 2025. The company has successfully addressed previous non-compliances under SEBI (LODR) Regulations, 2015, which led to the initial suspension. Upon resumption, the shares will be traded in the 'Trade for Trade' category (BE series on NSE and T group on BSE), necessitating 100% delivery. A special pre-open session for relisted scrips will be conducted on the resumption date to facilitate price discovery.
Key Highlights
Trading in Vivimed Labs equity shares will officially resume on BSE and NSE starting December 18, 2025.
The revocation follows the company's compliance with SEBI (LODR) Regulations, 2015, addressing prior regulatory lapses.
Shares will be placed in the 'Trade for Trade' segment (BE/T group), meaning every trade must result in delivery and no intraday netting is permitted.
A special pre-open session for relisted scrips will be held on December 18, 2025, to determine the opening price.
The notice of revocation was issued by the exchanges on December 10, 2025.
👀 What to Watch
Existing shareholders should prepare for the resumption of liquidity on December 18, 2025, and monitor the special pre-open session for price discovery. Investors should note the 'Trade for Trade' restriction, which requires full payment and delivery for all buy and sell transactions.
Vivimed Labs Proposes Pre-Packaged Insolvency Resolution Process at EGM
Vivimed Labs Limited held an Extraordinary General Meeting (EGM) on December 10, 2025, to seek shareholder approval for initiating a pre-packaged insolvency resolution process under the Insolvency and Bankruptcy Code, 2016. The company proposed this as a Special Resolution to address its financial obligations and restructure debt. Remote e-voting for the proposal was conducted between December 7 and December 9, 2025. The final outcome of the vote will determine the company's path toward legal debt resolution and operational restructuring.
Key Highlights
EGM held on December 10, 2025, specifically to vote on initiating a pre-packaged insolvency resolution process.
The proposal was presented as a Special Resolution under the Insolvency and Bankruptcy Code (IBC), 2016.
Remote e-voting period lasted from 9:00 AM on December 7 to 5:00 PM on December 9, 2025.
The meeting was conducted via Video Conferencing and concluded at 3:30 PM IST.
Final voting results and the Scrutinizer's Report are pending official declaration on the company website.
👀 What to Watch
Investors should be extremely cautious as insolvency proceedings typically signal severe financial distress and often result in significant equity dilution or loss for existing shareholders. It is advisable to monitor the NCLT's acceptance of the filing and the subsequent resolution plan.
Vivimed Labs Seeks Shareholder Approval for Pre-Packaged Insolvency Resolution Process
Vivimed Labs Limited held an Extraordinary General Meeting (EGM) on December 10, 2025, to seek approval for a Special Resolution to initiate a pre-packaged insolvency resolution process under the Insolvency and Bankruptcy Code, 2016. The remote e-voting for this critical decision was conducted between December 7 and December 9, 2025. This move indicates significant financial distress and a formal attempt to restructure the company's debt and obligations. The final voting results, which will determine the company's legal path forward, are expected to be released shortly.
Key Highlights
Special Resolution proposed to initiate pre-packaged insolvency resolution process under the IBC, 2016.
Extraordinary General Meeting (EGM) held on December 10, 2025, via Video Conferencing.
Remote e-voting period conducted from December 7 (9:00 AM) to December 9 (5:00 PM), 2025.
Management addressed shareholder queries regarding the insolvency application during the 30-minute meeting.
Final voting results to be declared and submitted to stock exchanges following the Scrutinizer's report.
👀 What to Watch
Investors should be extremely cautious as insolvency proceedings often result in significant equity dilution or total loss of value for shareholders. It is advisable to wait for the final voting results and subsequent NCLT updates before making any further investment decisions.
